This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Innovative Drugs To Transform European Alzheimer's Disease Medication Market By 2015, Says Frost & Sullivan

LONDON, Nov. 14, 2012 /PRNewswire/ -- The patent expiry of all four existing EMEA approved drugs for Alzheimer's disease (AD) by 2015 is likely to cause a steep decline in the growth of the European AD medication market. However, the approval of next generation therapies that can delay disease progression and restore cognitive functions are expected to revive opportunities in the market from 2015 to 2018.

New analysis from Frost & Sullivan ( http://www.healthcare.frost.com), European Alzheimer's Disease Medication Market, estimates the market to earn $1.80 billion in 2012 and reach $4.78 billion in 2019, growing at a compound annual growth rate (CAGR) of 15.1% from 2012-2019.

"Increasing R&D activity and a strong pipeline of disease modifying drugs bode well for market expansion," notes Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. "Considerable unexplored opportunities and the commercial goldmine that is the AD medication market have motivated several pharmaceutical and biotechnology companies to invest in R&D, particularly targeting the moderate-to-severe patient group."

Existing drug classes for AD offer poor therapeutic efficacy. The core focus of new R&D approaches has therefore centered on novel disease modifying drugs.

"These drugs are expected to offer potential benefits over conventional therapeutic options as they are safer, more effective and aim to prevent or slow down disease progression rather than provide just symptomatic relief," adds Chidambaram. "Therefore, these new drugs are expected to command premium prices and fuel market growth."

A key challenge at present is the looming patent expiry of key blockbuster drugs including Aricept, Exelon Patch and Ebixa. Their going off-patent is set to unleash a flood of cheaper generic equivalents that will result in lowered market revenues.

The accurate diagnosis of AD, especially in the early stages and monitoring of disease progression, will play a vital role in promoting proper market segmentation and positioning of drugs by market participants.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,082.55 -120.82 -0.66%
S&P 500 2,096.26 -11.52 -0.55%
NASDAQ 4,964.4840 -15.4170 -0.31%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs